Thanks CPR. That pretty much addresses most of my questions. So...

First 8 Last

Share
Profile

Follow
Sojourner

6,497 Posts.

1889

10/02/20

13:36

Post #: 42841219
Share

Originally posted by CPR ↑

Hi Sojourner,
In a similar boat and I think your concerns about IP are worth some consideration. See following discussion between JS and Alan Kohler below

I would say there are vulnerabilities with regard to IP, despite the fact that methoxyflurane is quite difficult to manufacture. There has also I believe been comments relating to the delivery device IP ownership by MVP (eg. the actual green whistle). The delivery devices are very simple devices which vaporize the liquid for inhalational use (could be replicated easily). However these do obviously require a process of testing/validation over time to meet standards and get to market. With enough financial motivation I think a big pharma would be able to overcome these issues of manufacture of the drug and delivery to patient. Probably key for MVP is to establish themselves as a market/brand leader worldwide.
Additionally it does sound like their continuous flow manufacturing process is quite ahead of the game and may moving forward offer significant competitive advantage (subsequent manufacture cost and eventual price points etc.) if there was competition in this space a significant time down the track.

from recent interview
"
Are you absolutely convinced that no-one else can come up with a non-opioid effective pain relief as Penthrox is?Yeah, we are absolutely convinced. Penthrox is a very tricky thing to make. We have our new continuous flow technology which gives us a competitive advantage around manufacturing efficiencies and cost. The drug itself is a generic, so it’s been around for 40 years. There’s no patent protection over the drug itself but there is patent protection over the deliver devices and intellectual property around making it.Right, but the fact that it’s a generic drug means that others can produce it, right?Yeah, if they can. It’s not an easy thing to make. Look, I think when we get to half the numbers that we’ve been talking about earlier in the “blue sky” discussion, then obviously people will be tempted. But for the moment, and for the years gone by, it hasn’t been an issue."

Expand

Thanks CPR. That pretty much addresses most of my questions. So there is no IP on methoxyflurane. There is IP on the delivery device, and there is arguably some moat around the manufacture of the drug.

Not rock solid, but good enough to hopefully become the 800 pound gorilla in the market before others get interested in trying to create a generic product.

Is that how everyone is interpreting it? I'd be interested in how others are assessing this risk.

MVP Price at posting: $10.38 Sentiment: Buy Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 35 more messages in this thread...

First 8 Last

Add MVP (ASX) to my watchlist

(20min delay)
Last 45.5¢		Change 0.000(0.00%)		Mkt cap ! $39.26M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	720	45.0¢

Sellers (Offers)

Price($)	Vol.	No.
46.0¢	4534	2

View Market Depth

No.	Vol.	Price($)
1	720	0.450
1	6302	0.440
1	4575	0.435
1	20000	0.430
2	25024	0.420

Price($)	Vol.	No.
0.460	4534	2
0.470	10058	2
0.475	1535	1
0.480	5000	1
0.485	1020	1

Last trade - 10.04am 07/05/2024 (20 minute delay)

MVP (ASX) Chart

Day chart unavailable

Thanks CPR. That pretty much addresses most of my questions. So...

Featured News

Tamboran is listing on the NYSE, and Wall Street is paying attention

Maiden drilling at West Arunta hints at major IOCG system for Rincon

Westpac tracks lower in profits in first half of 2024, with a 16% yoy drop amid slowing economy

Sold out signs go up for RIU Resources Roundup in Sydney

Mantle Minerals to kick off drilling at Mt Berghaus in WA

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks CPR. That pretty much addresses most of my questions. So...

Featured News

Top Stories

Tamboran is listing on the NYSE, and Wall Street is paying attention

Maiden drilling at West Arunta hints at major IOCG system for Rincon

Westpac tracks lower in profits in first half of 2024, with a 16% yoy drop amid slowing economy

Sold out signs go up for RIU Resources Roundup in Sydney

Mantle Minerals to kick off drilling at Mt Berghaus in WA

Buyers (Bids)

Sellers (Offers)

Featured News